Category Archives: Corporate News

Medizone determines regulatory pathway for the AsepticSure® System, a revolutionary disinfection technology, following meeting with U.S. FDA

Kalamazoo, Michigan, January 18, 2018.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® system, today announced that as a result of its meeting with representatives of the U.S. Food and Drug Administration (“FDA”) on January 18, 2018, it has reached decisions regarding the regulatory pathway for approval of the system and the additional information that must be generated to support a marketing application.

Medizone’s President and Chief Medical Officer, Dr. Michael Shannon commented, “Our discussions with the FDA regarding the regulatory pathway for approval of AsepticSure® were positive, productive, detailed and specific.  During the discussions, the FDA stated its position that there is no predicate device that is substantially equivalent to AsepticSure® because of its unique method of action.  As a result, we will apply for De Novo classification of the system.  Furthermore, we now have a clear understanding of the additional testing that we will need to conduct and the additional data that we will need to submit to support our De Novo application. We anticipate being able to perform the additional testing and to provide the additional data within a few months, which would permit us to submit an application for De Novo classification by the end of the third quarter.  If our application for De Novo classification is granted, we believe we will enjoy a significant competitive advantage over other disinfection technologies.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

For more information, visit:

http://www.medizoneint.com

Email: [email protected]

Medizone International Attending the J.P. Morgan 36th Annual Healthcare Conference for Partnership and Investment Discussions

KALAMAZOO, Mich., December 27, 2017: Medizone International, Inc. (OTCQB: MZEI) announced today the Company’s management will be attending the J.P. Morgan 36th Annual Healthcare Conference in San Francisco January 8th through 11th. Attending the conference will be Medizone’s CEO David Dodd and Medizone’s Chairman of the Board David Esposito. The company will be meeting with potential business partners and investment partners in support of the commercial development of AsepticSure®.

Medizone International, Inc., CEO David Dodd commented, “AsepticSure® represents a superior disinfectant technology compared to conventional systems or practices, providing over a thousand-times improvement in the reduction of pathogens, validated to disinfect to the sterilization standard of a 6-log reduction, representing greater than 99.9999% reduction.  To-date, our data demonstrates that AsepticSure® achieves 100% kill on 100% of surfaces, 100% of the time on 100% of pathogens – what we call the, ‘AsepticSure® 100% Rule’.  With the product approved for widespread commercialization, we are actively discussing with potential business partners and investment partners various options to achieve and grow AsepticSure® into the standard for disinfection and decontamination across multiple markets worldwide.”

 

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone  released the AsepticSure® System for use in multiple markets worldwide.

 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

 

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

Email: [email protected]

Shareholder Update

Dear fellow shareholders,

 

I’ve had the pleasure of serving as CEO of Medizone International, Inc. (“Medizone”) for three months.  During this time, many of you have communicated with me, conveying your best wishes for me in this position, as well as expressing various comments related to our business.  Thank you for your well wishes and support.  Also, your input and comments are appreciated.  I’m very pleased to have joined Medizone, both as a shareholder and to serve in this leadership position.

 

My goals include the following:

 

  • Achieve the necessary regulatory approvals that enable the commercialization of AsepticSure® for broad use in disinfection within a broad scope of markets (e.g., healthcare; pharmaceutical/laboratory industry; military; sports industry; etc.) throughout the world;
  • Establish a commercial operation that utilizes internal and external expertise to achieve strong commercial penetration and adoption of AsepticSure® within our targeted markets, globally, supporting continued growth and expansion of our business;
  • Build a capital structure that allows the execution of a financing plan that enables the Company to successfully pursue the necessary regulatory approvals and commercial operations in support of achieving a profitable, revenue generating business providing highly attractive shareholder value while delivering improved disinfection control to industry markets worldwide;
  • Improve health and lives worldwide through the adoption and use of AsepticSure®.

 

Along with you, we at Medizone share the excitement of the many opportunities apparent to utilize AsepticSure® in eliminating pathogens (bacteria, viruses and fungi) that can threaten the health and lives of millions throughout the world.

 

In order to achieve the business success that we seek, there are critical steps we must achieve:

 

  • Having AsepticSure® approved for sale for the specific uses, markets and geographic regions that we wish to pursue;
  • Having a business organization that supports the commercialization of AsepticSure®, as well as the manufacturing/distribution of AsepticSure® necessary to achieve our commercialization goals;
  • Having a capital base that supports our ability to achieve all necessary regulatory, commercial and operational requirements in support of our business plans.

 

Many long-term shareholders may feel that these points are obvious, have been recognized for years and, should have been “checked-off” in the past.  Regardless, they haven’t been and, yet they must be addressed in order for AsepticSure® to proceed successfully into market adoption, resulting in revenue development and improved shareholder value.  Let me address each of these points…

 

Regulatory Approvals, Status & Plans

 

  • EPA registration was achieved, November 14, 2016; prior to this date, AsepticSure® did not have this critical recognition that supports the ability to widely sell the product;
  • Global Engineering Safety Certification of Compliance was obtained June 29, 2017, making AsepticSure® compliant with the necessary engineering safety standards for 142 countries – without this, the product would not be able to receive CE Mark and most hospitals require such certification in consideration of purchasing/using such systems within their facilities;
  • CE mark was obtained, October 13, 2017; this achievement occurred much sooner than previously anticipated.  Having the CE mark allows us to sell AsepticSure® in Europe; however, in some countries, additional approvals may be required related to specific country disinfectant regulations;
  • FDA – our 513(g) Pre-submission was achieved November 7, 2017. We are scheduled to meet with the FDA on January 18, 2018; in advance of the meeting, we will receive feedback from the FDA relative to our pre-submission document;

o   As reported in April 2017, the FDA has determined that AsepticSure® should be classified as a medical device, requiring their review and approval of our technology in order for us to sell AsepticSure® into the hospital/healthcare market.

o   The purpose of our 513(g) pre-submission and subsequent FDA interaction is to clarify the specific regulatory pathway in order to achieve the necessary FDA approval in order for us to fully commercialize AsepticSure® to the hospital/healthcare market in the U.S.

 

Having achieved the EPA registration, Global Engineering Safety Certification of Compliance and CE Mark enables us to focus on developing the AsepticSure® business in various industry markets.  Without these regulatory approvals, despite the impressive scientific data in support of AsepticSure®, meaningful revenue growth and development simply won’t occur.  For many years, while the scientific data regarding AsepticSure® has been impressive, we haven’t had the EPA registration, the Global Engineering Safety Certification of Compliance or CE Mark, much less, the outstanding FDA approval.  These are necessary to successfully penetrate various markets and begin to build a growing revenue base.  Today, our situation is vastly improved as a result of the EPA registration in 2016 and, in 2017, the Global Engineering Safety Certification of Compliance and CE Mark designation.

 

Our focus is to utilize the existing approval achievements to focus on those industry markets, across various geographies, to achieve initial adoption of AsepticSure® as an improved and better solution to the great challenges of pathogen disinfection.  Once our FDA regulatory path is clarified, we’ll focus on achieving the necessary FDA approval in order to support an aggressive pursuit of AsepticSure®adoption within the U.S. hospital/healthcare market.  At this time, we can’t provide any FDA-approval timeframe, since we have yet to meet with the FDA.  Updates will be provided as our discussions with the FDA continue.

 

Commercial Operations; Status & Plans

 

The scientific data in support of AsepticSure® are impressive, to say the least.  In our opinion, we have demonstrated unsurpassed disinfection results versus competitive products and technologies.  Our results reflect disinfection performance across multiple industry markets, following rigid and scientifically sound protocols.  In order to successfully commercialize AsepticSure®, resulting in widespread adoption and use worldwide, we have several hurdles to overcome.

 

  • Currently, our organization is not structured and staffed to appropriately address the various market opportunities, routinely commercializing AsepticSure® to prospective customers.
  • We continue to build a distributor network, most recently in the Nordic region (Aglon a/s), that provides the opportunity to penetrate various markets outside the U.S., but as with all distributor relationships, we need the ongoing internal distributor-support functions and activities, which we currently don’t have.
  • In order to support an anticipated growing business, we require manufacturing and supply relationships that will support growth in our business, enabling us to achieve widespread adoption and use of AsepticSure® in multiple industry markets worldwide.  This includes our recent agreements and relationships with Cogmedix and Innovasource to ensure that our manufacturing and product supply are conducted with regulatory compliant and highly respected partners.  In this manner, we are partnering with the highest quality, efficient and compliant partners that can assist in our efforts to expand our business.

 

Despite these challenges, we have recently brought in strong business experience and expertise that is focused on identifying and establishing available options for us to begin the process of building an ongoing base of users of our technology.  Prior to receiving the various approvals and certifications mentioned earlier, there was little likelihood to achieving a growing business.  Now, with these recent accomplishments, as well as our proceeding with the FDA 510(k) discussions, our outlook is improved and opportunities are available.  Our challenge, however, remains in having the necessary capital base to support the appropriate organization, activities and efforts in order to successfully build the AsepticSure® business.

 

Capital Structure and Development

 

Currently, our cash balance is insufficient to appropriately support the business building activities and operations that are necessary to achieve adoption and use of AsepticSure® in the various targeted industry markets and geographic regions.

 

At the end of First Quarter, 2017 we had approximately $23,000 in cash.  As a result of the private placement offering conducted during the Spring, we ended Second Quarter, 2017 with approximately $59,000 in cash.  In September, the board of directors approved another private placement offering, which resulted in our ending Third Quarter, 2017 with $60,500 in cash.  The September private placement offering remains available to qualified investors and we encourage any potentially interested shareholders to contact me ([email protected]) regarding participation in this offering.

 

Overall, we need a minimum capital raise of approximately $5 million, which will enable us to ensure that we are operating our business successfully, focused on growth in value, while addressing various longer-term, existing accounts payables.  Currently, I and others in management, the board of directors and, various consultants are deferring all salary payments and work-related expenses.  We are focused on what we consider are most critical to support our regulatory efforts [i.e., FDA 510(k) and various country-specific requirements], maintaining compliance with all financial regulatory reporting requirements, working to establish a commercialization basis for AsepticSure® and, securing additional capital to support the business.

 

In order to raise additional capital, we need a supportive capital structure.  In December 2016, you approved a 500 million authorized share count.  Considering current obligations and previous share/warrant reserves, we have approximately 40 million shares available to use in any further capital raise.  At our current share price, this share count will probably only support a capital raise of up to $1 million – far short of our needs.  The value of our current share count relative to possible capital raise will improve as we achieve increased share price.

 

Over the near-term, we expect to report on the upcoming FDA meeting, addressing the 510(k) approval-path for AsepticSure®.   In addition, we hope to report additional participation in the current private placement offering.  There are also various business building activities underway that may solidify, providing us with additional encouraging news to report.

 

In order to raise the capital necessary to support moving the AsepticSure® business forward to achieve the success we all seek, additional share count authorization will likely be required.  We are reviewing our current capital structure, evaluating various options that will support our long-term needs as a profitable, operating business.

 

Ultimately, the best way to increase our shareholder value is to report consistent, growing revenues resulting from sales and application of AsepticSure® technology.  However, the various steps outlined in this update have to be successfully completed in order for such success to proceed.  This is our focus and represents our goals.

 

Our Values

 

This initial update is intended to provide you meaningful information regarding our commitment, focus and efforts towards successfully establishing Medizone as a growing, profitable business, widely establishing AsepticSure® as the standard in disinfection/decontamination worldwide in multiple industry markets.  It is also intended to provide you with insight to my leadership style, philosophy and beliefs.

 

There are several values that we, at Medizone, share:

 

  • Transparency – we seek to be open regarding our activities, efforts and results, while ensuring that we are compliant with financial regulatory disclosure requirements;
  • Integrity – we agree to perform the services to our colleagues, customers, shareholders, stakeholders and others in an honest, fair manner, recognizing that we are seeking to provide a solution to improved health to millions worldwide, while delivering highly attractive investment returns to our shareholders and meaningful career opportunities to our team;
  • Quality & Customer Focus – we seek to provide the highest quality product/service at a fair price, along with the necessary support to ensure that our customers and those that benefit from our technology are fully satisfied and achieve the results we communicate in our business activities;
  • Competitiveness – we seek to be successful in our development and commercial activities, providing improved solutions based upon science, technology, manufacturing, distribution and other business activities; in summary, we seek to be the “best competitor” in the eyes of our customers and those that benefit from AsepticSure® and any future products/services we might offer; we seek to be classified as a “best investment” in the view of our shareholders and others in the investment community;
  • Innovation – we recognize that the pace of science and technology is such that we have to continuously adapt to changing needs related to infection control and decontamination.  While we can’t predict future needs, we seek to ensure that the products/services that we provide continue to meet the various market needs and regulatory expectations.

 

Again, I am delighted to have joined Medizone as the CEO.  I am proud to be a fellow shareholder.  While we face significant challenges, our opportunities are even greater.  I look forward to continued communications with you and, “thank you” for your continued support and investments into our Company.

 

Best regards,

David A. Dodd

CEO

Medizone International, Inc.

www.medizoneint.com

 

 

Medizone to meet with U.S. Food and Drug Administration regarding the AsepticSure® Disinfection System, a revolutionary disinfection technology

Kalamazoo, Michigan, November 28, 2017. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced that it will meet with representatives of the U.S. Food and Drug Administration (“FDA”) on January 18, 2018 to discuss the planned submission of a marketing application for AsepticSure®. The FDA has confirmed that Medizone’s pre-submission filing contains all necessary information to permit the FDA to proceed with further review of the submission.

 

Kalamazoo, Michigan, November 28, 2017. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced that it will meet with representatives of the U.S. Food and Drug Administration (“FDA”) on January 18, 2018 to discuss the planned submission of a marketing application for AsepticSure®. The FDA has confirmed that Medizone’s pre-submission filing contains all necessary information to permit the FDA to proceed with further review of the submission.

 

Medizone’s CEO, David A. Dodd commented, “Our discussions with the FDA regarding AsepticSure® have been detailed and productive. We are looking forward to reaching an understanding with the FDA regarding the appropriate regulatory pathway and supporting data for the device in the near future and to making any necessary regulatory filings promptly after reaching agreement. If the FDA concludes that our pathway to regulatory approval requires that we pursue De Novo reclassification, we believe that we will be able to demonstrate that the application for the AsepticSure® reclassification can be granted and that the FDA pathway will provide us with a significant competitive advantage over other disinfection systems.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

Medizone International concludes exclusive Product Supply and License Agreement with Innovasource

Kalamazoo, Michigan, November 1, 2017. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced the conclusion of an exclusive Product Supply and License Agreement (the “Supply Agreement”) with Innovasource, LLC, a leading manufacturer of cleaning, deodorizing and disinfecting products (“Innovasource”).

Pursuant to the Supply Agreement, Innovasource will supply its custom-formulated, EPA-registered hydrogen peroxide based disinfectant product to Medizone for use in the AsepticSure® Disinfection System. Innovasource also granted to Medizone an exclusive, non-transferable limited license to use Innovasource’s intellectual property in the marketing and sale of the AsepticSure® Disinfection System in the United States. The Supply Agreement has a five-year term that will automatically renew for successive two-year terms, unless Medizone or Innovasource elects to provide notice of non-renewal prior to the expiration of the initial term or a renewal term.

The Supply Agreement builds on a relationship between Innovasource and Medizone that commenced with the previously announced execution by the two companies of a Sales Representative Agreement in April 2017. Pursuant to the Sales Representative Agreement, Medizone authorized Innovasource to solicit sales of the AsepticSure® Disinfection System to specified major accounts and agreed to pay Innovasource a commission on the net receipts from such sales. Medizone and Innovasource are currently collaborating on efforts to sell the AsepticSure® Disinfection System to such accounts.

Medizone’s CEO, David A. Dodd, commented, “Our relationship with Innovasource is of great strategic importance to us. It provides us a secure source of supply of the highest quality hydrogen peroxide based disinfectant product that we can supply to users of the AsepticSure® Disinfection System as a subregistrant under Innovasource’s EPA registration. Furthermore, Innovasource’s marketing and sales strength permit us to address potential major customers that would otherwise be beyond our reach at this stage of our development. With the recent receipt of the CE Mark and with our focus on achieving FDA 510(k) clearance, we are highly committed to establishing a growing revenue base through the adoption and utilization of the AsepticSure® Disinfection System, providing significant improvement on conventional disinfecting systems.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The AsepticSure® System is EPA-approved, received the CE mark and is currently pursing FDA 510(k) registration.

About Innovasource LLC

Innovasource develops and markets environmentally-sustainable products for consumers and businesses. The company was founded in 2007 by a seasoned team with more than fifty years’ experience in regulated product and consumer packaged goods. Innovasource’s headquarters are in the Charlotte metropolitan region in Huntersville, North Carolina. For more information, go to: www.innovasource.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Appoints Philip Theodore to Executive Team

Kalamazoo, Michigan, October 31, 2017. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced the appointment of Philip A. Theodore, as its Executive Vice President — Operations and Administration, General Counsel and Corporate Secretary. Before joining Medizone, Mr. Theodore served in similar roles with four other public companies, serving most recently as Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary of Aeterna Zentaris Inc.

“We are very proud to welcome Phil to our leadership team. I have worked with Phil at several other companies over the past 20 years and, I am confident that Medizone will benefit greatly from his leadership, experience and expertise,” said David Dodd, CEO of Medizone. “In his role, Phil will be an invaluable asset in establishing the platform for value growth and development of our Company.”

Mr. Theodore added, “I am delighted to be joining Medizone at this exciting point in its commercialization of the AsepticSure® Disinfection System and the development of Medizone. The Company has demonstrated the superiority of the AsepticSure® System as a means of addressing a wide variety of disinfection challenges. I am looking forward to working with David and his team to create value for Medizone’s shareholders as the company addresses serious public health issues on a worldwide basis.”

Philip A. Theodore’s Background

Mr. Theodore is a graduate of the University of Cincinnati College of Law, and holds a B.A. (Political Science) from the University of Tennessee at Chattanooga. Before joining Medizone, he served in the positions noted above with Aeterna Zentaris, Inc. from October 2014 through July 2017. Prior to joining Aeterna Zentaris, he served as Vice President, General Counsel and Corporate Secretary of Zep Inc. from July 2010 through September 2014; as Senior Vice President and General Counsel of John H. Harland Company, from September 2006 to September 2007; and as Vice President, General Counsel and Corporate Secretary of Serologicals Corporation from 2004 through August 2006. Mr. Theodore was a partner in the corporate practice of King & Spalding, LLP, an Atlanta-based law firm, from 1986 through 2003.

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The AsepticSure® System is EPA-approved, received the CE mark and is currently pursuing FDA 510(k) registration.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com

Email: [email protected]

The AsepticSure® Disinfection System Introduced to Nordic Region

AsepticSure®, the only disinfection system in the world that routinely achieves a minimum microbial kill of at least a thousand times greater than conventional cleaning methods, will be distributed in the Nordic Region by Aglon a/s

 

Stavanger, Norway and Kalamazoo, Michigan, October 30, 2017.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, and Aglon a/s. today announced that they have entered into an agreement for the introduction and distribution of AsepticSure® in the Nordic Region (the “Distribution Agreement”). Medizone granted Aglon a/s exclusive distribution rights for the AsepticSure® system in Norway, Sweden, Denmark, Finland and Iceland.

Medizone’s CEO, David A. Dodd commented, “We are very pleased to expand our distribution network with the addition of Aglon a/s as our exclusive distributor in the Nordic Region.  We are confident that Aglon has the ability and commitment to successfully commercialize AsepticSure® in this important market.  With our recent receipt of the EU CE Mark designation for AsepticSure®, we are looking forward to expanding our distributor relationships throughout the EU.”.

“Our Company is proud and excited to spearhead Medizone International’s introduction to the European market. Through this agreement to represent and market Medizone International’s unique disinfection technology in the Nordic countries, we hope to play a central part in building continued success for the AsepticSure® system, both in medical and non-medical markets. We have eagerly awaited this opportunity and are ready to proceed towards a successful commercialization of the AsepticSure® system, commented Aglon’s CEO Mr. Bent Rørvik and Chairman Stein I. Modahl, M.D.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone.  After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network.  The AsepticSure® System is EPA-approved, received the CE mark and is currently pursuing FDA 510(k) registration.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act.  Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations.  The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

The AsepticSure® Disinfection System, a revolutionary disinfection technology, Receives CE Mark

Kalamazoo, Michigan, October 16, 2017.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced that it is now allowed to place the “CE” Mark on the AsepticSure® System for distribution in the European Union (EU) and its member states.

Medizone’s CEO, David A. Dodd commented, “The receipt of CE Mark approval is a significant and important step in the commercial development of AsepticSure® in key European markets, which is an integral element in our international growth strategy for this game-changing product and technology.  The CE Mark validates product adherence to the European Commission’s quality assurance and safety requirements, while providing an unprecedented solution to ensuring disinfection of all pathogens.”  

The European market for disinfection technologies represents a multi-billion-dollar market for both healthcare and non-healthcare use that has consistently demonstrated rapid adoption of innovative technologies compared to other industrialized markets.  Well established distribution channels within member countries present numerous opportunities to accelerate the growth of AsepticSure® in the market.

Further commenting on the significance of the availability of the AsepticSure® System for the European market, Michael E. Shannon, M.A., M.Sc., M.D., Medizone President & Director, Medical Affairs, noted, “Using conventional double cleaning practices or disinfection technology, it is simply not possible to achieve even a 3-log (99.9%) bactericidal and virucidal kill throughout an entire targeted room.  AsepticSure® routinely achieves a minimum kill at least a thousand times greater than conventional cleaning methods across all pathogens on all surfaces within a contaminated space.  We are delighted to see our advanced technology now available to the European market and look forward to the acceptance and adoption of AsepticSure® within both healthcare and non-healthcare environments throughout Europe.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane

for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.  

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International to Host Investor Conference Call 

Medizone International to Host Investor Conference Call 

KALAMAZOO, MICH. September 18, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company will host a webcast and conference call today, September 18, 2017, to discuss the recent leadership transition, current priorities and its commercial strategy.

 

Investor Conference Call Details

Date: Monday, September 18, 2017                          Time: 10 AM EST

Materials for the Investor Conference Call will be made available at 7:00 AM EST on September 18, 2017

The slides can be accessed HERE.

Telephone:

North American callers, dial 800 681 1924.  International callers, dial +1 303 223 4393

There is no access code required.  Simply call into the assigned phone number.  

 

An archive of the slides will be available at www.medizoneint.com A replay of the conference call will be available from September 18, 2017 at 12:00 PM EST through September 25, 2017 at 12:00 PM EST by calling 800 633 8284. The access code for the replay is 21859116.  The slides, conference call, and replay are open to all interested parties.

 

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure® system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International announces the appointment of David A. Dodd as new Chief Executive Officer

Kalamazoo, MI, September 18, 2017 — Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacterial and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company has appointed David A. Dodd as Chief Executive Officer and as a member of the Company’s Board of Directors.

Effective September 18, 2017, David A. Esposito, current Chairman and interim CEO, will step down from his duties as interim CEO and will remain as Chairman of the Board of Directors.

“As Medizone continues to refine and execute plans to significantly expand our commercial operations, we are thrilled to have David A. Dodd lead our company into this new phase of growth,” commented David A. Esposito. “David brings a tremendous amount of successful experience as a CEO in various life science companies and our board is very confident in his ability to drive growth and value for the company and our shareholders.”

Over the last 12 months, AsepticSure® has been proven to provide significant disinfection in a number of critical need areas such as fitness centers, preparation rooms in funeral homes, building remediation and medicinal nurseries.  These areas provide significant opportunity for growth in the United States and in many markets across the world.  In addition, the Company is seeking FDA clearance for AsepticSure® as a medical device to be used in healthcare environments in the United States.

“On behalf of our employees, the board, and shareholders, I want to thank David Esposito for his leadership during his time as interim CEO.  David’s leadership and strategic planning skills have well positioned the Company for commercial success in the near term,” commented Mr. Dodd.  “I look forward to working with the Board and leading the Company as we build our commercial team to drive sales of AsepticSure® in markets around the world.  I would also like to recognize the effort and commitment of Dr. Michael Shannon, President and Director of Medical Affairs.  Dr. Shannon will continue to play a critical role as we translate the clinical utility of AsepticSure® into commercial success.”

Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial US customers for AsepticSure®.  The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

The company will hold a conference call on Monday, September 18, 2017 at 10:00 AM EST to discuss the transition and the commercial strategy moving forward.  Call in details and presentation materials will be made available on the company’s website prior to the call (www.medizoneint.com).  Please submit questions to be addressed on the call to John Pentony, Investor Relations ([email protected]).

 

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure® system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

www.medizoneint.com

Email: [email protected]

 

Medizone International, Inc. (OTCQB: MZEI)

350 East Michigan Avenue – Suite 500
Kalamazoo, MI 49007

Telephone: (269) 202-5020

Email: [email protected]

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

Social Media


Twitter:


https://twitter.com/asepticsure